Regeneron Pharmaceuticals, Inc. $REGN Shares Bought by Banco Santander S.A.

Banco Santander S.A. increased its stake in Regeneron Pharmaceuticals, Inc. (NASDAQ:REGN) by 263.7% in the 3rd quarter, according to its most recent Form 13F filing with the Securities & Exchange Commission. The firm owned 71,135 shares of the biopharmaceutical company’s stock after purchasing an additional 51,577 shares during the quarter. Banco Santander S.A. owned about 0.07% of Regeneron Pharmaceuticals worth $39,997,000 at the end of the most recent quarter.

Other large investors have also recently bought and sold shares of the company. Dodge & Cox raised its position in shares of Regeneron Pharmaceuticals by 64.6% during the second quarter. Dodge & Cox now owns 3,826,283 shares of the biopharmaceutical company’s stock worth $2,008,799,000 after purchasing an additional 1,502,198 shares during the period. Norges Bank acquired a new stake in Regeneron Pharmaceuticals during the 2nd quarter worth about $628,151,000. Acadian Asset Management LLC raised its holdings in Regeneron Pharmaceuticals by 234.7% during the 2nd quarter. Acadian Asset Management LLC now owns 465,740 shares of the biopharmaceutical company’s stock worth $244,480,000 after buying an additional 326,583 shares during the period. Loomis Sayles & Co. L P lifted its stake in Regeneron Pharmaceuticals by 18.6% during the second quarter. Loomis Sayles & Co. L P now owns 1,941,070 shares of the biopharmaceutical company’s stock valued at $1,019,062,000 after buying an additional 305,089 shares in the last quarter. Finally, Invesco Ltd. boosted its holdings in shares of Regeneron Pharmaceuticals by 26.5% in the second quarter. Invesco Ltd. now owns 1,075,824 shares of the biopharmaceutical company’s stock worth $564,808,000 after buying an additional 225,078 shares during the period. Institutional investors and hedge funds own 83.31% of the company’s stock.

Insider Buying and Selling

In related news, Director Huda Y. Zoghbi sold 1,638 shares of the company’s stock in a transaction on Thursday, February 19th. The shares were sold at an average price of $781.33, for a total transaction of $1,279,818.54. Following the completion of the sale, the director directly owned 1,703 shares of the company’s stock, valued at approximately $1,330,604.99. This represents a 49.03% decrease in their position. The transaction was disclosed in a filing with the Securities & Exchange Commission, which is accessible through this hyperlink. Also, SVP Jason Pitofsky sold 2,036 shares of Regeneron Pharmaceuticals stock in a transaction on Monday, February 9th. The stock was sold at an average price of $778.52, for a total transaction of $1,585,066.72. Following the completion of the transaction, the senior vice president owned 4,272 shares in the company, valued at $3,325,837.44. This trade represents a 32.28% decrease in their position. The SEC filing for this sale provides additional information. Insiders have sold a total of 5,274 shares of company stock valued at $4,142,738 in the last quarter. Company insiders own 7.02% of the company’s stock.

Wall Street Analysts Forecast Growth

Several equities research analysts recently commented on REGN shares. Truist Financial reduced their price target on shares of Regeneron Pharmaceuticals from $820.00 to $818.00 and set a “buy” rating for the company in a research report on Monday, February 2nd. Cantor Fitzgerald raised their target price on Regeneron Pharmaceuticals from $740.00 to $800.00 and gave the stock an “overweight” rating in a research report on Monday, February 2nd. Canaccord Genuity Group lifted their price target on Regeneron Pharmaceuticals from $850.00 to $1,057.00 and gave the company a “buy” rating in a report on Thursday, December 4th. Bank of America raised Regeneron Pharmaceuticals from an “underperform” rating to a “buy” rating and increased their price objective for the stock from $627.00 to $860.00 in a research note on Wednesday, January 7th. Finally, Evercore raised their price objective on Regeneron Pharmaceuticals from $750.00 to $875.00 and gave the stock an “outperform” rating in a research report on Thursday, January 22nd. Two investment analysts have rated the stock with a Strong Buy rating, fourteen have assigned a Buy rating and nine have given a Hold rating to the company. Based on data from MarketBeat, the stock presently has a consensus rating of “Moderate Buy” and an average price target of $793.81.

Regeneron Pharmaceuticals Stock Down 1.7%

Regeneron Pharmaceuticals stock opened at $770.79 on Friday. The company has a current ratio of 4.13, a quick ratio of 3.39 and a debt-to-equity ratio of 0.09. Regeneron Pharmaceuticals, Inc. has a 1-year low of $476.49 and a 1-year high of $821.11. The firm’s fifty day simple moving average is $771.32 and its 200-day simple moving average is $679.14. The company has a market capitalization of $81.49 billion, a P/E ratio of 18.55, a P/E/G ratio of 2.11 and a beta of 0.40.

Regeneron Pharmaceuticals (NASDAQ:REGN) last issued its quarterly earnings data on Friday, January 30th. The biopharmaceutical company reported $11.44 earnings per share (EPS) for the quarter, topping analysts’ consensus estimates of $10.74 by $0.70. Regeneron Pharmaceuticals had a net margin of 31.41% and a return on equity of 13.04%. The firm had revenue of $3.88 billion during the quarter, compared to analysts’ expectations of $3.76 billion. During the same period in the prior year, the company posted $12.07 earnings per share. Regeneron Pharmaceuticals’s revenue for the quarter was up 2.5% on a year-over-year basis. Sell-side analysts forecast that Regeneron Pharmaceuticals, Inc. will post 35.92 earnings per share for the current fiscal year.

Regeneron Pharmaceuticals Increases Dividend

The business also recently announced a quarterly dividend, which will be paid on Thursday, March 5th. Investors of record on Friday, February 20th will be issued a $0.94 dividend. This is an increase from Regeneron Pharmaceuticals’s previous quarterly dividend of $0.88. The ex-dividend date is Friday, February 20th. This represents a $3.76 annualized dividend and a yield of 0.5%. Regeneron Pharmaceuticals’s dividend payout ratio is presently 9.05%.

Regeneron Pharmaceuticals Profile

Regeneron Pharmaceuticals, Inc (NASDAQ: REGN) is a U.S.-based biotechnology company founded in 1988 and headquartered in Tarrytown, New York. It focuses on discovering, developing, manufacturing and commercializing medicines for serious medical conditions. The company combines laboratory research, clinical development and in-house manufacturing to advance a pipeline of biologic therapies across multiple therapeutic areas.

Regeneron is known for its proprietary drug discovery technologies, including its VelocImmune platform, which is used to generate fully human monoclonal antibodies.